Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Electrocore ( (ECOR) ) has shared an update.
On January 20, 2026, ElectroCore provided preliminary, unaudited guidance indicating it expects record full-year 2025 revenue of approximately $31.8–$32.0 million, representing about 26% growth over 2024’s $25.2 million, with fourth-quarter 2025 revenue anticipated at $9.0–$9.2 million, roughly 30% higher than the prior-year period. The company reported that it ended 2025 with about $11.6 million in cash, cash equivalents and marketable securities, down from $13.2 million as of September 30, 2025, and said it plans to give a more detailed operational and financial update with its full fourth-quarter and full-year 2025 results in March 2026, underscoring continued top-line expansion but also highlighting the importance of cash management for investors and other stakeholders.
The most recent analyst rating on (ECOR) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Electrocore stock, see the ECOR Stock Forecast page.
Spark’s Take on ECOR Stock
According to Spark, TipRanks’ AI Analyst, ECOR is a Neutral.
The score is held back primarily by weak financial quality—ongoing losses, cash burn, and balance-sheet deterioration (negative equity and higher debt). Technicals are moderately supportive with price above major moving averages, but momentum is somewhat stretched. The latest earnings call adds a modest positive from raised revenue guidance and strong growth, tempered by delayed profitability and legal/military-sales uncertainties.
To see Spark’s full report on ECOR stock, click here.
More about Electrocore
ElectroCore, Inc., based in Rockaway, N.J., is a bioelectronic technology company focused on improving health and quality of life through non-invasive neuromodulation. Its leading prescription products, gammaCore non-invasive vagus nerve stimulation (nVNS) and the Quell neurostimulator, are used to treat chronic pain syndromes, while its Truvaga and TAC-STIM handheld devices target the wellness and human performance market using similar bioelectronic technologies.
Average Trading Volume: 62,296
Technical Sentiment Signal: Buy
Current Market Cap: $57.09M
For detailed information about ECOR stock, go to TipRanks’ Stock Analysis page.